Recruiting
Phase 2

MAX-001

Sponsor:

Maxona Pharmaceuticals, Inc.

Code:

NCT07937657

Conditions

Impacted Third Molar Tooth

Tooth Extraction Status Nos

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

MAX-001

Placebo

Study Details

Brief summary:

This is a single center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of MAX-001 in participants with post-operative dental pain after wisdom teeth removal.

Conditions

Impacted Third Molar Tooth

Tooth Extraction Status Nos

Study ID

NCT07937657

Start date

Nov 10, 2026

Status verified date

Nov, 2026

Completion date

Jun, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Body mass index (BMI) between 18 to 35.0 kg/m\^2, inclusive
  • Scheduled to undergo elective bilateral mandibular third molar extraction under local anesthesia. This extraction has to involve a full or partial bony impaction confirmed by panoramic X-ray.
  • In good health and capable of undergoing oral surgery under the anesthesia protocol as described
  • No recent surgery within 2 months prior to Screening and no additional planned surgeries during the course of the study and for the 2 months following
  • No clinically significant abnormalities as determined by medical history, physical examination, clinical labs, and 12-lead electrocardiogram (ECG) at screening and clinical research unit (CRU) admission
  • Normal vital signs at screening and before surgery

Exclusion Criteria:

  • History of any illness or any clinical condition that, in the opinion of the Investigator, might confound the results of the trial or pose an additional safety risk in administering study drug to the participant. These include, but are not limited to:

1. Any lifetime antecedent of seizures, including childhood febrile seizures, any form of epilepsy, or any morbidity (including any history of head trauma with loss of consciousness) or medication that increases the risk of seizures or any family history of seizures or epilepsy
2. Evidence or history of other clinically significant acute or chronic infectious, autoimmune, hematologic (including sickle cell disease), dermatologic (including any active cutaneous disease, or other disease, at the surgical site), gastrointestinal (GI), respiratory, renal, urologic (including any history of urinary hesitancy or retention in males), hepatic, cardiovascular, ocular, metabolic, endocrine, neurologic, or psychiatric disease, or other clinically significant pathology, that, in the opinion of the Investigator, may preclude safe participation in this trial or compromise the interpretation of the data
3. History of cancer, except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ (all 3 with no recurrence for the last 5 years)
4. Participants with a history of ischemic heart disease (stable or unstable angina, myocardial infarction, or coronary revascularization), cerebrovascular disease (stroke, transient ischemic attack (TIA), cervical artery dissection, or cerebral revascularization), peripheral vascular disease (including vasospastic disease, arterial dissection or revascularization), congestive heart failure, clinically significant valvular heart disease, uncontrolled or poorly controlled hypertension or ECG derived left ventricular hypertrophy (LVH) with associated ST-T wave abnormalities, 2nd or 3rd degree heart block and PR interval >210 msec, QT interval corrected using Fridericia's formula (QTcF) > 450 msec in men and > 470 msec in women, QRS prolongation > 120 msec, history of atrial or ventricular arrhythmias, or has a family history of long QT syndrome or sudden cardiac death or other risk factors for torsades de pointes (e.g., hypokalemia)
5. Participants with narrow angle glaucoma
6. Participants with a current history of migraine headaches, back, neck, or hip pain or other acute or chronic pain conditions (including fibromyalgia) that might affect evaluations in the study
7. Based on Columbia-Suicide Severity Rating Scale (C-SSRS) results, participants with active suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS should be excluded
  • Has an ongoing active dental infection
  • Any condition at screening or baseline (e.g., GI, or hepatic conditions such as chronic diarrhea, colitis, inflammatory bowel syndrome (IBS), hepatitis, hepatic steatosis or cirrhosis, or prior surgery of the GI tract, including bariatric and weight loss surgeries) that may interfere with drug absorption or any disease or condition that is likely to affect drug metabolism or excretion
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values >1.5 × upper limit of normal (ULN)
  • Estimated creatinine clearance (CrCl) <60 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN at screening or at CRU admission
  • History of, or current infection with any of the following: human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HbsAg), or hepatitis C antibody (HCVAb).
  • History of febrile illness, influenza, or Coronavirus 2019 (COVID-19) symptoms or a positive polymerase chain reaction (PCR) test for COVID-19 within 28 days prior to screening or known close exposure to contact(s) with clinical COVID-19 symptoms within the last 14 days
  • History of chronic daily use of opioids or NSAIDs within 30 days prior to Screening or is opioid tolerant, i.e., the participant is currently taking or has taken an opioid for more than 30 consecutive days of daily use for pain in the 2 months prior to surgery
  • Use of new medications or new dosing regimens within 30 days prior to Screening
  • Has a known bleeding disorder or is taking agents affecting coagulation preoperatively. Participants who are taking low dose acetylsalicylic acid (ASA) prophylactically must agree and be able to discontinue use 14 days prior to surgery
  • A history of or current substance or alcohol use disorder per Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 within the past 2 years, or recent use (in the last month) of any recreational drugs, or regularly drinks on average more than 3 units of alcohol (3 shots of distilled beverages, 3 beers, or 3 glasses of wine) per day.
  • Positive results from a urine screen for recreational drugs/substances of abuse or from an alcohol breath test at screening or at CRU admission, including positive screen for cannabinoids.
  • Female participants who are pregnant, nursing, or planning to become pregnant during the trial or within 30 days after the last study drug dose
  • Male participants with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 30 days after the last study drug dose
  • Participated in any previous MAX-001 study or has exposure to an investigational product in a clinical study within 90 days of screening or 5.5 half-lives, whichever is longer

Study Design

Enrollment

276 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Dose Level 1 - Low Dose

Participants will receive 6 (30 mg) tablets or matching placebo tablets for an initial loading dose followed by 2 (30 mg) tablets twice daily.

experimental: Dose Level 2 - Medium Dose

Participants will receive 6 (30 mg) tablets or matching placebo tablets for an initial loading dose followed by 2 (30 mg) tablets twice daily.

experimental: Dose Level 3 - High Dose

Participants will receive 6 (30 mg) tablets for an initial loading dose followed by 2 (30 mg) tablets twice daily.

placebo comparator: Matching placebo

Participants will receive 6 matching placebo tablets for an initial loading dose followed by 2 matching placebo tablets twice daily.

Interventions

MAX-001

30 mg oral tablets

Placebo

matching placebo

Primary outcome measure

  • Summed Pain Intensity Difference 12 hours (SPID12) vs placebo using the Numerical Pain Rating Scale (NPRS) for pain [ Time Frame: 12 hours ]
  • Incidence of Treatment Emergent Adverse Events (TEAEs) as assessed by patient response to questions and spontaneous reporting of TEAEs [ Time Frame: 7 days ]

Central Contacts and Locations

Locations

CenExel JBR

Recruiting

Salt Lake City, Utah, United States, 84107

Contacts

Principal Investigator:

Todd M Bertoch, MD

More Information

Sponsor

Maxona Pharmaceuticals, Inc.

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Keywords

  • Wisdom Tooth
  • Wisdom Teeth

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Maxona Pharmaceuticals, Inc. on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.